Pfizer (PFE) Given a $41.00 Price Target by Morgan Stanley Analysts

Morgan Stanley set a $41.00 target price on Pfizer (NYSE:PFE) in a report issued on Friday morning. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on the stock. UBS Group set a $40.00 price target on shares of Pfizer and gave the company a buy rating in a research report on Wednesday, December 6th. BMO Capital Markets restated a buy rating and issued a $39.00 price target on shares of Pfizer in a research report on Friday, November 10th. Vetr upgraded shares of Pfizer from a hold rating to a buy rating and set a $38.82 price target for the company in a research report on Thursday, November 23rd. Zacks Investment Research upgraded shares of Pfizer from a hold rating to a buy rating and set a $40.00 price target for the company in a research report on Tuesday, October 3rd. Finally, Jefferies Group set a $39.00 price target on shares of Pfizer and gave the company a neutral rating in a research report on Thursday, November 16th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $38.88.

Pfizer (NYSE:PFE) opened at $36.86 on Friday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. Pfizer has a 12-month low of $30.90 and a 12-month high of $37.35. The stock has a market cap of $219,294.42, a P/E ratio of 22.75, a price-to-earnings-growth ratio of 2.46 and a beta of 1.01.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 18.69% and a return on equity of 25.41%. The firm had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the prior year, the company posted $0.61 EPS. The company’s revenue was up .9% on a year-over-year basis. equities research analysts predict that Pfizer will post 2.59 earnings per share for the current year.

Pfizer announced that its board has authorized a stock buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback programs are usually an indication that the company’s leadership believes its stock is undervalued.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a dividend of $0.34 per share. The ex-dividend date of this dividend is Thursday, February 1st. This is a boost from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a dividend yield of 3.69%. Pfizer’s dividend payout ratio is 79.01%.

In related news, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.00, for a total transaction of $249,750.00. Following the transaction, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares in the company, valued at $4,145,349.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,450 shares of company stock valued at $1,065,220. 0.06% of the stock is currently owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Shine Investment Advisory Services Inc. bought a new position in shares of Pfizer in the second quarter valued at $102,000. Mckinley Capital Management LLC Delaware bought a new position in shares of Pfizer in the second quarter valued at $103,000. D. Scott Neal Inc. lifted its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares in the last quarter. Herndon Capital Management LLC bought a new position in shares of Pfizer in the second quarter valued at $120,000. Finally, Americafirst Capital Management LLC bought a new position in shares of Pfizer in the third quarter valued at $127,000. 69.75% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This piece was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.com-unik.info/2018/01/06/pfizer-pfe-given-a-41-00-price-target-by-morgan-stanley-analysts.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)

What are top analysts saying about Pfizer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit